Copyright Reports & Markets. All rights reserved.

Global Systemic Mastocytosis Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Systemic Mastocytosis Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Systemic Mastocytosis Treatment Market Size Growth Rate by Product
      • 1.4.2 AK-002
      • 1.4.3 BLU-285
      • 1.4.4 Brentuximab Vedotin
      • 1.4.5 Crenolanib Besylate
      • 1.4.6 Cromolyn Sodium
      • 1.4.7 Others
    • 1.5 Market by End User
      • 1.5.1 Global Systemic Mastocytosis Treatment Market Size Growth Rate by End User
      • 1.5.2 Clinic
      • 1.5.3 Hospital
      • 1.5.4 Homecare
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Systemic Mastocytosis Treatment Market Size
      • 2.1.1 Global Systemic Mastocytosis Treatment Revenue 2014-2025
      • 2.1.2 Global Systemic Mastocytosis Treatment Sales 2014-2025
    • 2.2 Systemic Mastocytosis Treatment Growth Rate by Regions
      • 2.2.1 Global Systemic Mastocytosis Treatment Sales by Regions
      • 2.2.2 Global Systemic Mastocytosis Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Systemic Mastocytosis Treatment Sales by Manufacturers
      • 3.1.1 Systemic Mastocytosis Treatment Sales by Manufacturers
      • 3.1.2 Systemic Mastocytosis Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Systemic Mastocytosis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Systemic Mastocytosis Treatment Revenue by Manufacturers
      • 3.2.1 Systemic Mastocytosis Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Systemic Mastocytosis Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Systemic Mastocytosis Treatment Price by Manufacturers
    • 3.4 Systemic Mastocytosis Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Systemic Mastocytosis Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Systemic Mastocytosis Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Systemic Mastocytosis Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Systemic Mastocytosis Treatment Sales by Product
    • 4.2 Global Systemic Mastocytosis Treatment Revenue by Product
    • 4.3 Systemic Mastocytosis Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Systemic Mastocytosis Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Systemic Mastocytosis Treatment by Countries
      • 6.1.1 North America Systemic Mastocytosis Treatment Sales by Countries
      • 6.1.2 North America Systemic Mastocytosis Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Systemic Mastocytosis Treatment by Product
    • 6.3 North America Systemic Mastocytosis Treatment by End User

    7 Europe

    • 7.1 Europe Systemic Mastocytosis Treatment by Countries
      • 7.1.1 Europe Systemic Mastocytosis Treatment Sales by Countries
      • 7.1.2 Europe Systemic Mastocytosis Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Systemic Mastocytosis Treatment by Product
    • 7.3 Europe Systemic Mastocytosis Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Systemic Mastocytosis Treatment by Countries
      • 8.1.1 Asia Pacific Systemic Mastocytosis Treatment Sales by Countries
      • 8.1.2 Asia Pacific Systemic Mastocytosis Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Systemic Mastocytosis Treatment by Product
    • 8.3 Asia Pacific Systemic Mastocytosis Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Systemic Mastocytosis Treatment by Countries
      • 9.1.1 Central & South America Systemic Mastocytosis Treatment Sales by Countries
      • 9.1.2 Central & South America Systemic Mastocytosis Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Systemic Mastocytosis Treatment by Product
    • 9.3 Central & South America Systemic Mastocytosis Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Systemic Mastocytosis Treatment by Countries
      • 10.1.1 Middle East and Africa Systemic Mastocytosis Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Systemic Mastocytosis Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Systemic Mastocytosis Treatment by Product
    • 10.3 Middle East and Africa Systemic Mastocytosis Treatment by End User

    11 Company Profiles

    • 11.1 AB Science SA
      • 11.1.1 AB Science SA Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 AB Science SA Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 AB Science SA Systemic Mastocytosis Treatment Products Offered
      • 11.1.5 AB Science SA Recent Development
    • 11.2 AbbVie Inc
      • 11.2.1 AbbVie Inc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 AbbVie Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 AbbVie Inc Systemic Mastocytosis Treatment Products Offered
      • 11.2.5 AbbVie Inc Recent Development
    • 11.3 Arog Pharmaceuticals Inc
      • 11.3.1 Arog Pharmaceuticals Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Arog Pharmaceuticals Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Arog Pharmaceuticals Inc Systemic Mastocytosis Treatment Products Offered
      • 11.3.5 Arog Pharmaceuticals Inc Recent Development
    • 11.4 Blueprint Medicines Corp
      • 11.4.1 Blueprint Medicines Corp Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Blueprint Medicines Corp Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Blueprint Medicines Corp Systemic Mastocytosis Treatment Products Offered
      • 11.4.5 Blueprint Medicines Corp Recent Development
    • 11.5 Bristol-Myers Squibb Company
      • 11.5.1 Bristol-Myers Squibb Company Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Bristol-Myers Squibb Company Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Bristol-Myers Squibb Company Systemic Mastocytosis Treatment Products Offered
      • 11.5.5 Bristol-Myers Squibb Company Recent Development
    • 11.6 Deciphera Pharmaceuticals LLC
      • 11.6.1 Deciphera Pharmaceuticals LLC Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Deciphera Pharmaceuticals LLC Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Deciphera Pharmaceuticals LLC Systemic Mastocytosis Treatment Products Offered
      • 11.6.5 Deciphera Pharmaceuticals LLC Recent Development
    • 11.7 Novartis AG
      • 11.7.1 Novartis AG Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Novartis AG Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Novartis AG Systemic Mastocytosis Treatment Products Offered
      • 11.7.5 Novartis AG Recent Development
    • 11.8 Patara Pharma Inc
      • 11.8.1 Patara Pharma Inc Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Patara Pharma Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Patara Pharma Inc Systemic Mastocytosis Treatment Products Offered
      • 11.8.5 Patara Pharma Inc Recent Development
    • 11.9 Seattle Genetics Inc
      • 11.9.1 Seattle Genetics Inc Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Seattle Genetics Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Seattle Genetics Inc Systemic Mastocytosis Treatment Products Offered
      • 11.9.5 Seattle Genetics Inc Recent Development
    • 11.10 Stemline Therapeutics Inc
      • 11.10.1 Stemline Therapeutics Inc Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Stemline Therapeutics Inc Systemic Mastocytosis Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Stemline Therapeutics Inc Systemic Mastocytosis Treatment Products Offered
      • 11.10.5 Stemline Therapeutics Inc Recent Development

    12 Future Forecast

    • 12.1 Systemic Mastocytosis Treatment Market Forecast by Regions
      • 12.1.1 Global Systemic Mastocytosis Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Systemic Mastocytosis Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Systemic Mastocytosis Treatment Market Forecast by Product
      • 12.2.1 Global Systemic Mastocytosis Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Systemic Mastocytosis Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Systemic Mastocytosis Treatment Market Forecast by End User
    • 12.4 North America Systemic Mastocytosis Treatment Forecast
    • 12.5 Europe Systemic Mastocytosis Treatment Forecast
    • 12.6 Asia Pacific Systemic Mastocytosis Treatment Forecast
    • 12.7 Central & South America Systemic Mastocytosis Treatment Forecast
    • 12.8 Middle East and Africa Systemic Mastocytosis Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Systemic Mastocytosis Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Systemic Mastocytosis Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Systemic Mastocytosis Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Systemic Mastocytosis Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Systemic Mastocytosis Treatment in these regions.
      This research report categorizes the global Systemic Mastocytosis Treatment market by top players/brands, region, type and end user. This report also studies the global Systemic Mastocytosis Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      AB Science SA
      AbbVie Inc
      Arog Pharmaceuticals Inc
      Blueprint Medicines Corp
      Bristol-Myers Squibb Company
      Deciphera Pharmaceuticals LLC
      Novartis AG
      Patara Pharma Inc
      Seattle Genetics Inc
      Stemline Therapeutics Inc

      Market size by Product
      AK-002
      BLU-285
      Brentuximab Vedotin
      Crenolanib Besylate
      Cromolyn Sodium
      Others
      Market size by End User
      Clinic
      Hospital
      Homecare

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Systemic Mastocytosis Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Systemic Mastocytosis Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Systemic Mastocytosis Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Systemic Mastocytosis Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Systemic Mastocytosis Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Systemic Mastocytosis Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now